Tue Feb 25 10:16:12 UTC 2025: ## Hyderabad-Based Biological E. to Manufacture Chikungunya Vaccine, Creating Hundreds of Jobs
**Hyderabad, India (February 25, 2025)** – Biological E. (BE), a Hyderabad-based vaccine manufacturer, has partnered with Bavarian Nordic to produce the latter’s Chikungunya vaccine for low and middle-income countries (LMICs). This collaboration marks the first partnership to expand global access to the Chikungunya vaccine and will create up to 300 new jobs in Hyderabad.
The agreement involves a technology transfer from Bavarian Nordic to BE, initially focusing on the drug product manufacturing process. Future plans include transferring the drug substance process as well. Bavarian Nordic will retain its manufacturing capacity for Western markets.
BE’s existing facilities in Genome Valley, Hyderabad, will be upgraded to accommodate Chikungunya vaccine production. Following regulatory approvals, commercial manufacturing is expected to begin.
The partnership builds on Bavarian Nordic’s strategy to expand global access to its vaccine, following recent approvals in the US and a positive opinion from the European Medicines Agency. BE’s Managing Director, Mahima Datla, highlighted the company’s manufacturing capabilities and commitment to meeting health needs in endemic regions. Bavarian Nordic’s President and CEO, Paul Chaplin, praised BE’s expertise and experience. This collaboration is expected to significantly increase the availability of the Chikungunya vaccine in regions where it is most needed.
First Piper 